Sugi Predict

Sugi Predict / Compounds / SCHEMBL2687745

SCHEMBL2687745

SCHEMBL2687745

Nc1c(S(=O)(=O)O)cc(Nc2cccc(S(=O)(=O)CCOS(=O)(=O)O)c2)c2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GNG2 P59768 5/20 0.71
▸ GNB1 P62873 5/20 0.71
▸ PHLPP2 Q6ZVD8 2/20 0.71
▸ CYP1A2 P05177 2/20 0.71
▸ CYP2C9 P11712 2/20 0.71
▸ ALOX15 P16050 2/20 0.71
▸ HSD17B10 Q99714 2/20 0.71
▸ ALDH1A1 P00352 1/20 0.71
▸ CYP3A4 P08684 1/20 0.71
▸ HPGD P15428 1/20 0.71
▸ MAPK1 P28482 1/20 0.71
▸ CYP2C19 P33261 1/20 0.71
▸ HIF1A Q16665 1/20 0.71
▸ P2RY4 P51582 9/20 0.64
▸ CHAT P28329 2/20 0.56
▸ ENPP3 O14638 1/20 0.56
▸ ENPP1 P22413 1/20 0.56
▸ P2RY2 P41231 6/20 0.52
▸ P2RY12 Q9H244 5/20 0.52
▸ P2RY6 Q15077 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30870099 1.00 GNG2 (0.71) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL19921893 0.99 GNG2 (0.70) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL9176117 0.91 GNG2 (0.70) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL2686350 0.90 GNG2 (0.68) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL16541422 0.90 GNG2 (0.68) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL10017872 0.89 GNG2 (0.76) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL19708510 0.89 GNG2 (0.76) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL11598798 0.88 GNG2 (0.74) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL13290349 0.87 GNG2 (0.78) GNG2GNB1PHLPP2CYP1A2CYP2C9
SCHEMBL15339733 0.86 GNG2 (0.65) GNG2GNB1PHLPP2CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6149692-A Method and composition for incorporating radiation-absorbing agents into polymers NOVARTIS AG (CH) 2000-11-21 — — US claimed
US-12441845-B2 Siloxane monomer, contact lens composition and contact lens PEGAVISION CORPORATION (TW) 2025-10-14 — — US disclosed
US-12384865-B2 Contact lens material and contact lens PEGAVISION CORPORATION (TW) 2025-08-12 — — US disclosed
US-20240132670-A1 SILOXANE MONOMER, CONTACT LENS COMPOSITION AND CONTACT LENS PEGAVISION CORPORATION (TW) 2024-04-25 — — US disclosed
EP-4345122-A1 SILOXANE MONOMER, CONTACT LENS COMPOSITION AND CONTACT LENS Pegavision Corporation (TW) 2024-04-03 — — EP disclosed
US-20230384498-A1 OPTICALLY ANISOTROPIC FILM, OPTICAL FILM, AND DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2023-11-30 — — US disclosed
US-20230358935-A1 OPTICAL FILM AND ELECTROLUMINESCENCE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2023-11-09 — — US disclosed
US-20230332048-A1 LIGHT ABSORPTION ANISOTROPIC FILM, OPTICAL FILM, AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2023-10-19 — — US disclosed
US-11493518-B2 Binding domain mapping George Mason Research Foundation, Inc. (US) 2022-11-08 — — US disclosed
US-20210115489-A1 NOVEL MEDIATOR KIKKOMAN CORPORATION (JP) 2021-04-22 — — US disclosed
US-20080057533-A1 Array for rapid detection of a microorganism KIMBERLY-CLARK WORLDWIDE, INC. 2008-03-06 — — US disclosed
US-20080057532-A1 Method for detecting Candida on skin KIMBERLY-CLARK WORLDWIDE, INC. 2008-03-06 — — US disclosed
US-20070269851-A1 Colorimetric Substrates, Colorimetric Sensors, and Methods of Use KCI LICENSING, INC., AS GRANTOR 2007-11-22 — — US disclosed
WO-2007063024-A2 KERATIN-BINDING EFFECTOR MOLECULES CONTAINING REACTIVE DYES BASF SE (DE) 2007-06-07 — — WO disclosed
US-20070107145-A1 Reactive dye composition and method of dyeing polyamide materials BANK OF AMERICA, N.A., FORMERLY LASALLE BANK NATIONAL ASSOCIATION 2007-05-17 — — US disclosed
US-20070107145-A1 Reactive dye composition and method of dyeing polyamide materials BANK OF AMERICA, N.A., FORMERLY LASALLE BANK NATIONAL ASSOCIATION 2007-05-17 — — US disclosed
US-5385842-A Anthraquinones as inhibitors of sulfide production from sulfate-reducing bacteria E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-01-31 — — US disclosed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 — — EP disclosed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 — — EP disclosed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115489-A1 NOVEL MEDIATOR MPO, EPX, LPO GNG2 2481/4885GNB1 3346/4885PHLPP2 4673/4885
US-11493518-B2 Binding domain mapping SNRPE, HSPBP1, CNBP GNG2 843/4885GNB1 551/4885PHLPP2 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.